Erste Asset Management GmbH Buys Shares of 19,494 Edwards Lifesciences Co. (NYSE:EW)

Erste Asset Management GmbH acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the third quarter, HoldingsChannel reports. The fund acquired 19,494 shares of the medical research company’s stock, valued at approximately $1,298,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BDF Gestion purchased a new position in shares of Edwards Lifesciences in the second quarter valued at about $5,148,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Edwards Lifesciences by 9.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock valued at $31,571,000 after buying an additional 40,348 shares during the last quarter. Raymond James & Associates lifted its holdings in shares of Edwards Lifesciences by 2.8% in the second quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock worth $168,597,000 after buying an additional 50,124 shares in the last quarter. AIA Group Ltd grew its stake in Edwards Lifesciences by 91.7% during the third quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after acquiring an additional 358,556 shares in the last quarter. Finally, RiverPark Advisors LLC lifted its stake in Edwards Lifesciences by 58.1% in the 3rd quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock worth $1,362,000 after purchasing an additional 7,583 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of a number of research reports. Truist Financial lowered their target price on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a research report on Friday, October 25th. Barclays increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a report on Monday. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $77.25.

Edwards Lifesciences Price Performance

EW stock opened at $70.19 on Wednesday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market capitalization of $41.40 billion, a PE ratio of 10.13, a price-to-earnings-growth ratio of 3.97 and a beta of 1.12. The business has a 50 day simple moving average of $68.24 and a 200-day simple moving average of $74.78.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the business posted $0.59 EPS. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,000 shares of company stock worth $2,657,000. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.